CLEVELAND AND PITTSBURGH, September 21, 2017 –  BioMotiv, a drug development accelerator, and the University of Pittsburgh announced the launch of Koutif Therapeutics, which is developing an inhibitor of an E3 ligase (Fbxo3) to treat inflammatory conditions such as neuropathic pain, COPD, lung transplant rejection, and irritable bowel disease.


Koutif Therapeutics is based on intellectual property licensed from the University of Pittsburgh and the United States Department of Veterans Affairs. The technology was developed by Rama K. Mallampalli, MD, a Harrington Scholar, and Beibei Chen, PhD.